APLS - ROSEN A LEADING AND RANKED FIRM Encourages Apellis Pharmaceuticals Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action – APLS | Benzinga
NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) between January 28, 2021 and July 28, 2023, both dates inclusive (the "Class Period"), of the important October 2, 2023 lead plaintiff deadline.
SO WHAT: If you purchased Apellis common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Apellis class action, go to https://rosenlegal.com/submit-form/?case_id=17734 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 2, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, ...